VIDEO: New therapies herald 'exciting time' for multiple myeloma

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

I think what we're seeing is really an exciting time for patients with multiple myeloma, with the availability of a number of new therapeutics, including CAR T-cells that were recently approved by the Food and Drug Administration in 2022 to be available for patients. I think this really creates new options for patients with multiple myeloma, who have progressively exhausted multiple lines of treatment. And what's most interesting is that not only do you have the development of the set of CAR T-cells, but also the availability of bispecific molecules coming up and other immuno oncological approaches to the treatment of multiple myeloma. So I think what this does is shows that this area of immuno oncological treatments in multiple myeloma is going to undergo a pretty hyperdynamic period of development. I wouldn't view the availability of commercially approved, commercially available CAR T-cells as the end state. What you're going to see is a few things happen. One is there's going to be a ramp up period during which those centers that are available and approved for delivery of these therapeutics, like City of Hope, will be ramping up to make access available to patients. But you'll see continued study of how best to integrate these therapeutics into the care of patients. And as I think we'll see and have seen in the lymphoma space, progressively, I would expect CAR T-cells to be used earlier and earlier in the treatment of individuals with multiple myeloma. The key thing, and this is maybe the hard part, is to figure out how best to biologically risk segment patients with multiple myeloma, so those that are greatest risk of failure from the other alternative approaches would get speedier access to CAR T-cells. And I think that's the crux of the trials that you'll see in this phase four of development, as well as the thought process going on in expert centers, again like City of Hope, who are developing these therapeutics to patients.